Morgan Stanley Downgrades Centessa Pharmaceuticals to Underweight, Lowers Price Target to $5
Morgan Stanley analyst Matthew Harrison downgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Overweight to Underweight and lowers the price target from $10 to $5.